Overview

Ertugliflozin: Cardioprotective Effects on Epicardial Fat

Status:
Not yet recruiting

Trial end date:
2022-07-31

Target enrollment:
0

Participant gender:
All

Summary

The purpose of this study is to learn if Sodium-Glucose Cotransporter 2 inhibitor (SGLT2i) medications enhance beneficial properties of epicardial adipose tissue including metabolic flexibility, insulin sensitivity, decreased cell size and reduced inflammation.

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Stanford University

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

5-(4-chloro-3-(4-ethoxybenzyl)phenyl)-1-hydroxymethyl-6,8-dioxabicyclo(3.2.1)octane-2,3,4-triol
Ertugliflozin
Glipizide
Sodium-Glucose Transporter 2 Inhibitors

Criteria

Inclusion Criteria:

- patient at Stanford Cardiovascular Surgery clinic who is scheduled for cardiac bypass
surgery

- history of Diabetes Mellitus Type 2 currently taking metformin or diet-controlled

Exclusion Criteria:

- allergy or intolerance to interventional medication

- currently taking any anti-diabetic medication other than metformin